<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>bncsys, Author at Biotherapy Partners</title>
	<atom:link href="https://biotherapypartners.com/author/commited-to-tour-success/feed/" rel="self" type="application/rss+xml" />
	<link>https://biotherapypartners.com/author/commited-to-tour-success/</link>
	<description>Commited to your success</description>
	<lastBuildDate>Tue, 31 Oct 2023 10:46:10 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.5.2</generator>

<image>
	<url>https://biotherapypartners.com/wp-content/uploads/2022/12/cropped-logo_site_mini-32x32.png</url>
	<title>bncsys, Author at Biotherapy Partners</title>
	<link>https://biotherapypartners.com/author/commited-to-tour-success/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Biotherapy Partners will attend ESGCT 2023</title>
		<link>https://biotherapypartners.com/biotherapy-partners-will-attend-esgct-2023/</link>
					<comments>https://biotherapypartners.com/biotherapy-partners-will-attend-esgct-2023/#respond</comments>
		
		<dc:creator><![CDATA[bncsys]]></dc:creator>
		<pubDate>Thu, 26 Oct 2023 09:45:35 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://biotherapy-preprod.bncsys.eu/?p=1734</guid>

					<description><![CDATA[Biotherapy Partners will attend the conference of the European Society of Gene and Cell Therapy ... <a title="Biotherapy Partners will attend ESGCT 2023" class="read-more" href="https://biotherapypartners.com/biotherapy-partners-will-attend-esgct-2023/" aria-label="More on Biotherapy Partners will attend ESGCT 2023">Read more</a>]]></description>
										<content:encoded><![CDATA[
<h2 class="gb-headline gb-headline-7ce7d94d gb-headline-text">Biotherapy Partners will attend the conference of the European Society of Gene and Cell Therapy in Brussels, Belgium</h2>



<p>Olivier Negre, co-founder of Biotherapy Partners and Chief Scientific Officer of Smart Immune will give a presentation on CAR ProTcell platform developed by Smart Immune: CAR ProTcell, towards well-tolerated and persistent off-the-shelf allogeneic CAR-T cells. </p>



<p></p>



<p>To schedule a meeting, contact us at&nbsp;<a href="mailto:info@biotherapypartners.com">info@biotherapypartners.com</a>. </p>



<p>Biotherapy Partners is a consulting firm providing support for the development of Advanced Therapy Medicinal Products, especially gene and cell therapies</p>
]]></content:encoded>
					
					<wfw:commentRss>https://biotherapypartners.com/biotherapy-partners-will-attend-esgct-2023/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Biotherapy Partners will attend ATE 2023</title>
		<link>https://biotherapypartners.com/biotherapy-partners-will-attend-ate-2023/</link>
					<comments>https://biotherapypartners.com/biotherapy-partners-will-attend-ate-2023/#respond</comments>
		
		<dc:creator><![CDATA[bncsys]]></dc:creator>
		<pubDate>Thu, 26 Oct 2023 09:35:18 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://biotherapy-preprod.bncsys.eu/?p=1731</guid>

					<description><![CDATA[Biotherapy Partners will attend the conference Advance Therapy Europe in Estoril, Portugal Olivier Negre, co-founder ... <a title="Biotherapy Partners will attend ATE 2023" class="read-more" href="https://biotherapypartners.com/biotherapy-partners-will-attend-ate-2023/" aria-label="More on Biotherapy Partners will attend ATE 2023">Read more</a>]]></description>
										<content:encoded><![CDATA[
<figure class="wp-block-table"><table><tbody><tr><td>Biotherapy Partners will attend the conference Advance Therapy Europe in Estoril, Portugal</td></tr></tbody></table><figcaption class="wp-element-caption">Olivier Negre, co-founder of Biotherapy Partners and Chief Scientific Officer of Smart Immune<br>will give a presentation on the ProTcell platform developed by Smart Immune: Development of allogeneic CAR-T cells based on T cell progenitors</figcaption></figure>



<p></p>



<p>To schedule a meeting, contact us at&nbsp;<a href="mailto:info@biotherapypartners.com">info@biotherapypartners.com</a>. </p>



<p>Biotherapy Partners is a consulting firm providing support for the development of Advanced Therapy Medicinal Products, especially gene and cell therapies</p>
]]></content:encoded>
					
					<wfw:commentRss>https://biotherapypartners.com/biotherapy-partners-will-attend-ate-2023/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Biotherapy Partners will attend ITD 2023</title>
		<link>https://biotherapypartners.com/biotherapy-partners-attended-itd-2023-in-besancon-france/</link>
					<comments>https://biotherapypartners.com/biotherapy-partners-attended-itd-2023-in-besancon-france/#respond</comments>
		
		<dc:creator><![CDATA[bncsys]]></dc:creator>
		<pubDate>Tue, 03 Oct 2023 15:35:10 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://biotherapy-preprod.bncsys.eu/?p=1707</guid>

					<description><![CDATA[Biotherapy Partners will attend the conference Innovative Therapies Days 2023 in Besancon, France Olivier Negre, ... <a title="Biotherapy Partners will attend ITD 2023" class="read-more" href="https://biotherapypartners.com/biotherapy-partners-attended-itd-2023-in-besancon-france/" aria-label="More on Biotherapy Partners will attend ITD 2023">Read more</a>]]></description>
										<content:encoded><![CDATA[<div class="gb-container gb-container-5b1d3909">

<h2 class="gb-headline gb-headline-8899869e gb-headline-text"><strong>Biotherapy Partners will attend the conference Innovative Therapies Days 2023 in Besancon, France</strong></h2>

</div>


<p>Olivier Negre, co-founder of Biotherapy Partners and Chief Scientific Officer of Smart Immune will give a presentation on CAR ProTcell platform developed by Smart Immune: Designing next generation allogeneic T-cell therapies empowered by the thymus</p>



<p></p>



<p>To schedule a meeting, contact us at&nbsp;<a href="mailto:info@biotherapypartners.com">info@biotherapypartners.com</a>. </p>



<p>Biotherapy Partners is a consulting firm providing support for the development of Advanced Therapy Medicinal Products, especially gene and cell therapies</p>
]]></content:encoded>
					
					<wfw:commentRss>https://biotherapypartners.com/biotherapy-partners-attended-itd-2023-in-besancon-france/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Support for the preparation of an IND package</title>
		<link>https://biotherapypartners.com/support-for-the-preparation-of-an-ind-package/</link>
		
		<dc:creator><![CDATA[bncsys]]></dc:creator>
		<pubDate>Wed, 07 Jun 2023 15:15:23 +0000</pubDate>
				<category><![CDATA[Regulatory and operational support]]></category>
		<category><![CDATA[Cell Therapy]]></category>
		<guid isPermaLink="false">https://biotherapypartners.fr/?p=1545</guid>

					<description><![CDATA[The request A biotech startup requested a support to review, supplement and complete the necessary ... <a title="Support for the preparation of an IND package" class="read-more" href="https://biotherapypartners.com/support-for-the-preparation-of-an-ind-package/" aria-label="More on Support for the preparation of an IND package">Read more</a>]]></description>
										<content:encoded><![CDATA[
<h3 class="gb-headline gb-headline-16269d35 gb-headline-text">The request</h3>



<p>A biotech startup requested a support to review, supplement and complete the necessary documentation for a <strong>clinical trial application</strong></p>



<h3 class="gb-headline gb-headline-18814ee4 gb-headline-text">Biotherapy Partners approach</h3>



<p>A review of the existing documentation was acomplished, a gap analysis was done, additional studies were performed if necessary, reports were written, the dossier for clininical trial application was prepared filed to regulatory agency, questions from the agency were answered and the clinical trial was initiated.</p>



<h3 class="gb-headline gb-headline-4fb76de8 gb-headline-text">Results</h3>



<p>BP identified the gaps, proposed supplementary studies and contributed to finalize a successful clinicical trial application for FDA.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Strategic and operational support for the non-clinical development of a LBP (Live Biotherapeutic Product)</title>
		<link>https://biotherapypartners.com/strategic-and-operational-support-for-the-non-clinical-development-of-a-lbp-live-biotherapeutic-product/</link>
		
		<dc:creator><![CDATA[bncsys]]></dc:creator>
		<pubDate>Wed, 07 Jun 2023 15:12:33 +0000</pubDate>
				<category><![CDATA[Strategic and operational support]]></category>
		<category><![CDATA[Live Biotherapeutic Product]]></category>
		<guid isPermaLink="false">https://biotherapypartners.fr/?p=1543</guid>

					<description><![CDATA[The request Client obtained an inconclusive in vivo proof of concept study while literature offered ... <a title="Strategic and operational support for the non-clinical development of a LBP (Live Biotherapeutic Product)" class="read-more" href="https://biotherapypartners.com/strategic-and-operational-support-for-the-non-clinical-development-of-a-lbp-live-biotherapeutic-product/" aria-label="More on Strategic and operational support for the non-clinical development of a LBP (Live Biotherapeutic Product)">Read more</a>]]></description>
										<content:encoded><![CDATA[
<h3 class="gb-headline gb-headline-16269d35 gb-headline-text">The request</h3>



<p>Client obtained an inconclusive in vivo proof of concept study while literature offered ample supporting translational data.</p>



<h3 class="gb-headline gb-headline-18814ee4 gb-headline-text">Biotherapy Partners approach</h3>



<p>Biotherapy Partners reviewed existing data, analyzed the literature to provide a preclinical strategy &amp; plan. </p>



<p>BP executed the plan: RFI &amp; RFP to select appropriate CROs, conctracting and supervision of study to obtain critical preclinical proof of concept</p>



<h3 class="gb-headline gb-headline-4fb76de8 gb-headline-text">Results</h3>



<p>The client obtained in vivo proof of concept of efficacy enabling to secure its path towards clinical trials.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Strategic and operational support for the non-clinical development of a CAR T cell drug product</title>
		<link>https://biotherapypartners.com/strategic-and-operational-support-for-the-non-clinical-development-of-a-car-t-cell-drug-product/</link>
		
		<dc:creator><![CDATA[bncsys]]></dc:creator>
		<pubDate>Wed, 07 Jun 2023 15:10:45 +0000</pubDate>
				<category><![CDATA[Strategic and operational support]]></category>
		<category><![CDATA[Gene therapy]]></category>
		<guid isPermaLink="false">https://biotherapypartners.fr/?p=1541</guid>

					<description><![CDATA[The request A major investor requested experts of Biotherapy Partners to perform due diligence on ... <a title="Strategic and operational support for the non-clinical development of a CAR T cell drug product" class="read-more" href="https://biotherapypartners.com/strategic-and-operational-support-for-the-non-clinical-development-of-a-car-t-cell-drug-product/" aria-label="More on Strategic and operational support for the non-clinical development of a CAR T cell drug product">Read more</a>]]></description>
										<content:encoded><![CDATA[
<h3 class="gb-headline gb-headline-16269d35 gb-headline-text">The request</h3>



<p>A major <strong>investor</strong> requested experts of Biotherapy Partners to perform <strong>due diligence</strong> on academic created startup. A second phase, resulting from the Due Diligence, was to be the elaboration of a development plan and the strategic and operational support in the implementation of this plan.</p>



<h3 class="gb-headline gb-headline-18814ee4 gb-headline-text">Biotherapy Partners approach</h3>



<p>Their needs ranged from setting up a TPP, risk analysis and different early-stage procedures, to operational support in non-clinical, CMC and project management. </p>



<p>Biotherapy Partners team was involved at various levels in order to successfully develop the product developed by the partner company. </p>



<p>It has called upon its members with various expertises to resolve the various challenges encountered on the way to submitting the CTA. </p>



<p>It also provided strong operational support through the leadership of the R&amp;D team and project management.</p>



<h3 class="gb-headline gb-headline-4fb76de8 gb-headline-text">Results</h3>



<p>Our action allowed the company to secure the path to its first CTA submission, by eliminating or streamlining the various risks related to the product.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Cell and Gene Therapies: introduction to manufacturing and regulatory processes</title>
		<link>https://biotherapypartners.com/cell-and-gene-therapies-introduction-to-manufacturing-and-regulatory-processes/</link>
		
		<dc:creator><![CDATA[bncsys]]></dc:creator>
		<pubDate>Wed, 07 Jun 2023 15:08:55 +0000</pubDate>
				<category><![CDATA[Coaching & Training]]></category>
		<category><![CDATA[Gene therapy]]></category>
		<guid isPermaLink="false">https://biotherapypartners.fr/?p=1539</guid>

					<description><![CDATA[The request This training course provides an overview of considerations in the industry of cell ... <a title="Cell and Gene Therapies: introduction to manufacturing and regulatory processes" class="read-more" href="https://biotherapypartners.com/cell-and-gene-therapies-introduction-to-manufacturing-and-regulatory-processes/" aria-label="More on Cell and Gene Therapies: introduction to manufacturing and regulatory processes">Read more</a>]]></description>
										<content:encoded><![CDATA[
<h3 class="gb-headline gb-headline-16269d35 gb-headline-text">The request</h3>



<p>This <strong>training</strong> course provides an overview of considerations in the <strong>industry</strong> of <strong>cell and gene therapies</strong>. It is designed to create a solid framework for anyone looking to embark in the sector.</p>



<h3 class="gb-headline gb-headline-18814ee4 gb-headline-text">Biotherapy Partners approach</h3>



<p>BP prepared an overview of gene and cell therapy fundamentals and delivered it through interactive sessions</p>



<h3 class="gb-headline gb-headline-4fb76de8 gb-headline-text">Results</h3>



<p>Delegates develped their knowledge in cell and gene therapy and asked questions. </p>



<p>The training was a great opportunity to address questions and discuss topics reltated to ATMPs.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Biotherapy Partners will attend ISCT 2023</title>
		<link>https://biotherapypartners.com/isct-paris-2023/</link>
		
		<dc:creator><![CDATA[bncsys]]></dc:creator>
		<pubDate>Mon, 22 May 2023 10:50:00 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://biotherapypartners.fr/?p=1201</guid>

					<description><![CDATA[Biotherapy Partners will be attending ISCT Paris 2023 Come to visit the poster “The marketing ... <a title="Biotherapy Partners will attend ISCT 2023" class="read-more" href="https://biotherapypartners.com/isct-paris-2023/" aria-label="More on Biotherapy Partners will attend ISCT 2023">Read more</a>]]></description>
										<content:encoded><![CDATA[
<h2 class="gb-headline gb-headline-49646cf2 gb-headline-text">Biotherapy Partners will be attending ISCT Paris 2023</h2>



<p>Come to visit the poster “The marketing authorization of Advanced Therapy Medicinal Products under the regulation of the European Union” and meet us at the conference. </p>



<p>To schedule a meeting, contact us at&nbsp;<a href="mailto:info@biotherapypartners.com">info@biotherapypartners.com</a>. </p>



<p>Biotherapy Partners is a consulting firm providing support for the development of Advanced Therapy Medicinal Products, especially gene and cell therapies</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Biotherapy Partners will present a poster at ISCT 2023</title>
		<link>https://biotherapypartners.com/biotherapy-partners-will-present-a-poster-at-isct-2023/</link>
		
		<dc:creator><![CDATA[bncsys]]></dc:creator>
		<pubDate>Mon, 22 May 2023 09:54:00 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://biotherapypartners.fr/?p=1439</guid>

					<description><![CDATA[Biotherapy Partners will present a poster at ISCT 2023 annual meeting in Paris Biotherapy Partners ... <a title="Biotherapy Partners will present a poster at ISCT 2023" class="read-more" href="https://biotherapypartners.com/biotherapy-partners-will-present-a-poster-at-isct-2023/" aria-label="More on Biotherapy Partners will present a poster at ISCT 2023">Read more</a>]]></description>
										<content:encoded><![CDATA[
<h2 class="gb-headline gb-headline-3b1a0ca1 gb-headline-text">Biotherapy Partners will present a poster at ISCT 2023 annual meeting in Paris</h2>



<p>Biotherapy Partners contributed to the poster presenting the marketing authorization of advanced therapy medicinal products under the regulation of the European union.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Due diligence for cell therapy</title>
		<link>https://biotherapypartners.com/due-diligence-for-cell-therapy/</link>
		
		<dc:creator><![CDATA[bncsys]]></dc:creator>
		<pubDate>Mon, 15 May 2023 17:52:13 +0000</pubDate>
				<category><![CDATA[Due Diligence]]></category>
		<category><![CDATA[Cell Therapy]]></category>
		<guid isPermaLink="false">https://biotherapypartners.fr/?p=1357</guid>

					<description><![CDATA[The request Client was looking to complement its internal team with seasoned experts in cell ... <a title="Due diligence for cell therapy" class="read-more" href="https://biotherapypartners.com/due-diligence-for-cell-therapy/" aria-label="More on Due diligence for cell therapy">Read more</a>]]></description>
										<content:encoded><![CDATA[
<h3 class="gb-headline gb-headline-16269d35 gb-headline-text">The request</h3>



<p>Client was looking to <strong>complement its internal team</strong> with seasoned experts in cell therapy.</p>



<h3 class="gb-headline gb-headline-18814ee4 gb-headline-text">Biotherapy Partners approach</h3>



<p>BP reviewed existing data, focussing on critical, potentially deal-breaking data and interacts with third-party SMEs.</p>



<h3 class="gb-headline gb-headline-4fb76de8 gb-headline-text">Results</h3>



<p>BP pintpointed during due diligence key success factors for the deal &amp; next steps.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
